Phase II Study of TRC102 in Combination With Temozolomide for Recurrent Glioblastoma

Trial Profile

Phase II Study of TRC102 in Combination With Temozolomide for Recurrent Glioblastoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Temozolomide (Primary) ; TRC 102 (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 20 Mar 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Aug 2017.
    • 20 Mar 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top